World

Bharat Biotech’s partner Ocugen seeks approval for Covaxin in Canada

Our Bureau Hyderabad | Updated on July 16, 2021

As per the Canadian Government norms, a rolling submission facilitates faster review of the vaccine for approval

Ocugen Inc., Bharat Biotech's partner for USA and Canada for Covid-19 vaccine Covaxin, has initiated a rolling submission to Health Canada for the jab, the US company said in a regulatory filing.

As per the Canadian Government norms, a rolling submission facilitates faster review of the vaccine for approval on the safety, efficacy and quality data.

“We thank Health Canada for their upcoming review of Covaxin and look forward to working with them so that we can offer the possibility of another safe and effective option to be used in their fight against Covid-19 and its Delta variant,” Shankar Musunuri, Chairman of the Board, Chief Executive Officer and co-founder of Ocugen said.

Also read: Emergency Use Licence for Covaxin: Bharat Bio submits all documents to WHO

Early this month, Hyderabad-based Bharat Biotech announced that as per the safety and efficacy analysis of data from the phase 3 clinical trials, Covaxin is 77.8 percent effective against symptomatic Covid-19, according to Bharat Biotech.

It was found to be 93.4 percent effective against severe symptomatic Covid and had a 63.6 percent efficacy against asymptomatic pandemic, the company said.

Efforts are also on to obtain approval for Covaxin in the US. Last month, the US Food and Drug Administration has advised Ocugen to apply for approval for a full biological licence instead of an emergency use authorisation.

Published on July 16, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like